Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer by Joseph R. Scarpa, Giacomo Montagna, George Plitas, Amitabh Gulati, Amitabh Gulati, Gregory W. Fischer, Gregory W. Fischer, Joshua S. Mincer, Joshua S. Mincer

“…Both opioids and anti-PD-L1 ICI regulated RNA expression in this network, suggesting a nexus for opioid-ICI interaction. …”
Get full text

Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy by Kathleen A. O’Leary, Amber M. Bates, Won Jong Jin, Brian M. Burkel, Raghava N. Sriramaneni, Sarah E. Emma, Erin J. Nystuen, Elizabeth G. Sumiec, Suzanne M. Ponik, Zachary S. Morris, Linda A. Schuler

“…Abstract Background Most patients with estrogen receptor positive (ER+) breast cancer do not respond to immune checkpoint inhibition (ICI); the tumor microenvironment (TME) of these cancers is generally immunosuppressive and contains few tumor-infiltrating lymphocytes. …”
Get full text

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer by Xingyu Chen, Lixiang Feng, Yujing Huang, Yi Wu, Na Xie

“…Triple-negative breast cancer (TNBC) is characterized by a high rate of systemic metastasis, insensitivity to conventional treatment and susceptibility to drug resistance, resulting in a poor patient prognosis. …”
Get full text

Comprehensive Analysis of Innate Immunophenotyping Based on Immune Score Predicting Immune Alterations and Prognosis in Breast Cancer Patients by Weiguang Liu, Lingling Xia, Zhengmiao Xia, Liming Chen

“…To identify the effect innate immune checkpoint for breast cancer immunotherapy, the innate immune prognostic biomarkers were selected through the ICI score model and the risk model in breast cancer patients. …”
Get full text

A Breast Cancer Detection Problem using various Machine Learning Techniques in the Context of Health Prediction System by Najat Rafalia, Haitam Ettazi, Jaafar Abouchabaka

Get full text

Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer by Hsuan‐Chen Liu, Simone Capuani, Andrew A. Badachhape, Nicola Di Trani, Daniel Davila Gonzalez, Robin S. Vander Pol, Dixita I. Viswanath, Shani Saunders, Nathanael Hernandez, Ketan B. Ghaghada, Shu‐Hsia Chen, Elizabeth Nance, Ananth V. Annapragada, Corrine Ying Xuan Chua, Alessandro Grattoni

“…Abstract Immune checkpoint inhibitors (ICI), pembrolizumab and atezolizumab, were recently approved for treatment‐refractory triple‐negative breast cancer (TNBC), where those with Programmed death‐ligand 1 (PD‐L1) positive early‐stage disease had improved responses. …”
Get full text

Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1 by Nan Chen, Nicole Higashiyama, Valentina Hoyos

“…Preliminary studies suggest that mutations in breast cancer gene 2 (<i>BRCA-2</i>) are associated with increased immune infiltration and response to ICI therapy. …”
Get full text

Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer by Xiuying Li, Xianqin Luo, Shunqin Hu

“…However, the efficacy of monotherapy of ICIs was very limited. In this study, we endeavored to explore whether losartan can modulate the solid tumor microenvironment (TME) and improve the therapeutic efficacy of anti-PD-L1 mAb in 4T1 mouse breast tumor model and the underlying mechanism. …”
Get full text

Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response by Pierluigi De Santis, Martina Perrone, Chiara Guarini, Anna Natalizia Santoro, Carmelo Laface, Daniela Carrozzo, Gaia Rachele Oliva, Palma Fedele

“…Triple negative breast cancer (TNBC) represents an aggressive disease associated with a high risk of recurrence after curative treatment and a poor prognosis in the metastatic setting. …”
Get full text

Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy by Andrea Nicolini, Paola Ferrari, Angelo Carpi

“…<b>Methods:</b> This review summarizes the principal ongoing conventional and investigational immunotherapies in breast cancer. Particularly, immune checkpoint inhibitors (ICIs) and their use alone or combined with DNA damage repair inhibitors (DDRis) are described. …”
Get full text

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer by Xuan Ge, Susan E. Yost, Jin Sun Lee, Paul H. Frankel, Christopher Ruel, Yujie Cui, Mireya Murga, Aileen Tang, Norma Martinez, Samuel Chung, Christina Yeon, Daphne Stewart, Daneng Li, Swapnil Rajurkar, George Somlo, Joanne Mortimer, James Waisman, Yuan Yuan

“…This study investigated the safety and antitumor activity of aromatase inhibitors (AI) with immune checkpoint inhibitor (ICI) pembrolizumab in patients with hormone receptor positive (HR⁺) human epidermal growth factor receptor 2-negative (HER2⁻) metastatic breast cancer (MBC) in a phase II study with a safety lead-in (NCT 02648477). …”
Get full text

In Vitro Investigations of miR-33a Expression in Estrogen Receptor-Targeting Therapies in Breast Cancer Cells by Pelin Ozfiliz-Kilbas, Ozlem Sonmez, Pinar Obakan-Yerlikaya, Ajda Coker-Gurkan, Narcin Palavan-Ünsal, Pinar Uysal-Onganer, Elif Damla Arisan

“…Regulatory microRNAs (miRNAs) on lipid biosynthesis pathways as miR-33a have potential to clarify the exact mechanism. (2) Methods: We determined miR-33a expression levels following exposure of MCF-7 and MDA-MB-231 breast cancer cells to estrogen receptor (ER) activator (estradiol-17β, E2) or anti-estrogens (ICI 182,780, Fulvestrant, FUL) at non-cytotoxic concentrations. …”
Get full text

Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients by Federica Miglietta, Letizia Pontolillo, Carmine De Angelis, Roberta Caputo, Monica Marino, Emilio Bria, Rossana Di Rienzo, Annarita Verrazzo, Carlo Buonerba, Giampaolo Tortora, Giuseppe Di Lorenzo, Lucia Del Mastro, Mario Giuliano, Filippo Montemurro, Fabio Puglisi, Valentina Guarneri, Michelino De Laurentiis, Luca Scafuri, Grazia Arpino

“…Background: The last years have seen unprecedented improvement in breast cancer (BC) survival rates. However, this entirely apply to female BC patients, since gender minorities (male, transgender/gender-diverse) are neglected in BC phase III registration clinical trials. …”
Get full text

High FLT3 expression indicates favorable prognosis and correlates with clinicopathological parameters and immune infiltration in breast cancer by Rui Chen, Xinyang Wang, Jingyue Fu, Mengdi Liang, Tiansong Xia

“…Then we employed checkpoint-related molecules, immunophenoscore (IPS), and tumor mutation burden (TMB) to assess the efficacy of immuno-checkpoint inhibitors (ICIs). Pearson correlation coefficient was employed to exam the association between DNA methylation and FLT3 expression.Results: FLT3 displays an elevated expression in breast cancer than normal pairs and is significantly associated with multiple clinical characteristics like age, menopause status, histological type, pathological stage, and molecular subtype as well as increased overall survival (OS). …”
Get full text

An autophagy-related long non-coding RNA prognostic model and related immune research for female breast cancer by Jiafeng Chen, Jiafeng Chen, Xinrong Li, Xinrong Li, Shuixin Yan, Shuixin Yan, Jiadi Li, Jiadi Li, Yuxin Zhou, Yuxin Zhou, Minhua Wu, Jinhua Ding, Jiahui Yang, Yijie Yuan, Ye Zhu, Weizhu Wu

“…IntroductionBreast cancer (BRCA) is the most common malignancy among women worldwide. …”
Get full text

Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis by Juan Yang, Chen Liu, Yaru Guo, Wenwen Guo, Xiaojin Wu

“…BackgroundIn recent years, the addition of immune checkpoint inhibitors (ICI) to chemotherapy (CT) has become a research hotspot in the therapy of metastatic triple-negative breast cancer. …”
Get full text

Potential of Dietary HDAC2i in Breast Cancer Patients Receiving PD-1/PD-L1 Inhibitors by Yuqian Wang, Lingeng Lu, Changquan Ling, Ping Zhang, Rui Han

“…Breast cancer (BC) is a lethal malignancy with high morbidity and mortality but lacks effective treatments thus far. …”
Get full text

The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer by Ji Eun Choi, Jae Seok Lee, Min-Sun Jin, Ilias P. Nikas, Kwangsoo Kim, Sunah Yang, Soo Young Park, Jiwon Koh, Sohyeon Yang, Seock-Ah Im, Han Suk Ryu

“…ICIS-H was also shown to be an independent predictor of favorable OS (p = 0.003). …”
Get full text

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer by Hanne Vos, Kathleen Lambein, François Richard, Bram Mariën, Ines Nevelsteen, Kevin Punie, Hans Wildiers, Lieze Berben, Annouschka Laenen, Giuseppe Floris, Christine Desmedt, Ann Smeets

“…Abstract The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). …”
Get full text

A genomic instability-related lncRNA model for predicting prognosis and immune checkpoint inhibitor efficacy in breast cancer by Ying Jiao, Shiyu Li, Xuan Wang, Ming Yi, Hongqu Wei, Shanjie Rong, Kun Zheng, Li Zhang

“…Therefore, it is of interest to explore somatic mutator-derived lncRNAs in predicting the prognosis and ICI efficacy in breast cancer patients. In this study, the lncRNA expression data and somatic mutation data of breast cancer patients from The Cancer Genome Atlas (TCGA) were downloaded and analyzed thoroughly. …”
Get full text